Predictive Oncology Inc. (POAI) Reports Q1 Loss of $0.93
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Predictive Oncology Reports First Quarter 2020 Financial Results, Provides Business Update
June 8, 2020 4:16 PM EDTCancerQuest 2020 Study on Schedule for Completion in Q2 2020
NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to personalized medicine and drug discovery, today reported financial results for the quarter ended March 31, 2020 and provided a business update.
Financial and Business Highlights
Continued initial study to sequence ovarian tumors and validate reach back process; study is on schedule to be completed in the second quarter of 2020Developing a... More


